Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma
Author:
Funder
National Research Foundation of Korea
Korea Health Industry Development Institute
Ministry of Health and Welfare
Publisher
Korean Liver Cancer Association
Link
http://e-jlc.org/upload/pdf/jlc-19-1-1.pdf
Reference59 articles.
1. Hepatocellular carcinoma
2. Hepatocellular carcinoma
3. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
4. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
5. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis;Journal of Liver Cancer;2024-03-31
2. Exploring the potential of Toxoplasma gondii in drug development and as a delivery system;Experimental & Molecular Medicine;2024-02-01
3. Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities;Medical Oncology;2023-01-21
4. Differences between exhausted CD8+ T cells in hepatocellular carcinoma patients with and without uremia;Canadian Journal of Physiology and Pharmacology;2021-04
5. Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure;Journal of Liver Cancer;2020-03-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3